Orlandi L, Zaffaroni N, Gornati D, Veneroni S, Silvestrini R
Divisione di oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Anticancer Res. 1994 May-Jun;14(3A):1161-4.
The ability of lonidamine, an energolytic derivative of indazole-carboxylic acid, to modulate the cytotoxic activity of cisplatin was investigated on primary cultures obtained from 11 human ovarian carcinomas. A 72-h postincubation with lonidamine potentiated the activity of a 1-h cisplatin treatment. Statistical analysis of the dose-effect plots indicated that the interaction between the two drugs was synergistic in 4 tumors and additive in the remaining 7 tumors. The occurrence of the synergistic effect was independent of some biological characteristics of the tumor cell population, such as cell kinetics (as assessed by 3H-thymidine labeling index), DNA content and the expression of the putative factor of cisplatin resistance, glutathione-S-transferase pi.
研究了吲唑羧酸的能量分解衍生物氯尼达明对来自11例人卵巢癌的原代培养物中顺铂细胞毒性活性的调节能力。与氯尼达明孵育72小时后增强了1小时顺铂治疗的活性。剂量效应图的统计分析表明，两种药物之间的相互作用在4个肿瘤中是协同的，在其余7个肿瘤中是相加的。协同效应的发生与肿瘤细胞群体的一些生物学特性无关，如细胞动力学（通过3H-胸腺嘧啶核苷标记指数评估）、DNA含量和顺铂耐药假定因子谷胱甘肽-S-转移酶π的表达。
